Cel-Sci strengthening its manufacturing team and three promotions at Adolor – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Active pharmaceutical ingredients, Pharmaceutical industry, Glaxosmithkline

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Cel-Sci strengthening its manufacturing team and three promotions at Adolor.

Cel-Sci​ has appointed Todd Burkhart​ as vice president (VP) of manufacturing/facilities and commercial operations. The appointment follows the validation of Cel-Sci’s manufacturing facility.

Burkhart has more than 30 years experience in the production of biologics, medical devices and active pharmaceutical ingredients (API). This experience has been gained at companies including Cephalon, Human Genome Sciences and Univax Biologics.

Joel Beckerman​ has been appointed to the newly created position of senior manager of product marketing at MeadWestvaco (MWV)​. Beckerman has 15 years of pharma experience at companies including Abbott Laboratories, Pfizer and AstraZeneca.

Adolor ​has made three executive promotions to strengthen its management team. David Geoghegan ​has been promoted to VP, manufacturing. Geoghegan joined Adolor in 2004 as senior director, manufacturing process quality and has also worked at MedImmune.

In addition, Kevin Darryl White​ has been promoted to VP, regulatory affairs. White joined Adolor in 2008 and has also worked at Palatin Technologies and the US Food and Drug Administration (FDA).

Finally, Adolor has promoted Michael Adelman​ to the position of VP, marketing and sales. Adelman joined Adolor in 2008 after leaving AstraZeneca.

Roger Hickling​ has been appointed as R&D director at Phytopharm​. Hickling has more than 30 years experience in pharma R&D at SmithKline Beecham and Alizyme Therapeutics.

IRX Therapeutics​ has appointed Neil Berinstein ​as its chief scientific officer. Berinstein has worked with IRX as a consultant and has previously held positions at Sanofi Pasteur.

Richard Kenney​ has been appointed as VP, clinical development at Vical​. Before joining Vical Kenney worked at organisations including GlaxoSmithKline and the FDA.

Related topics: Markets & Regulations

Related news

Show more

Follow us


View more